PAH Exposure by Fowler, Paul A. et al.
Perspectives | Correspondence
A 140  v o l u m e  117 | n u m b e r  4 | April 2009  •  Environmental Health Perspectives
PAH Exposure
doi:10.1289/ehp.0800445
We were very interested to read the article by 
Choi et al. (2008). The difference between 
maternal exposure and our own data on 
actual concentrations of poly  cyclic aromatic 
hydro  carbons (PAHs) in the human male 
fetal liver (Fowler et al. 2008) was striking. 
Eight of the PAH exposures meas  ured by 
Choi et al. were also on our list of PAHs 
measured in the human fetal liver during the 
second trimester. 
Assuming that the 48‑hr samples of air‑
borne PAH exposure used by Choi et al. 
(2008) truly reflect longer‑term exposure 
more relevant to the outcomes under con‑
sideration (which is contentious because the 
measurements may either over  estimate or 
under  estimate true exposure), then we can 
approximate a comparison between the two 
studies. Therefore, we calculated the fold‑ 
difference between the maximal second tri‑
mester exposures (nanograms per cubic meter) 
reported by Choi et al. in their Table 2 and 
the mean male fetal liver values presented in 
our Table 3 [(Fowler et al. 2008), corrected 
to nanograms per kilogram dry weight]. We 
calculated values separately for fetuses from 
mothers who smoked cigarettes and for those 
who did not  (Table 1). The smallest differ‑
ence was 5‑fold for benzo[a]pyrene (BaP), 
whereas the largest difference was 8,340‑fold 
for benz[a]anthracene (BaA), in all cases 
representing accumulation in the fetal liver 
considerably above personal maternal expo‑
sure to airborne PAHs. Of course there are 
other sources of exposure to PAHs, such 
as air pollution and occupational sources, 
but these data very clearly suggest that large 
quantities of PAHs are crossing the placenta 
and accumulating in the fetus. Perhaps even 
more interesting was the very different rela‑
tive proportions of these eight PAHs in the 
air compared with in fetal livers: BaA com‑
prised 11% in air but 94–96% in the livers, 
whereas pyrene was 17% in the air but below 
detection in the livers. This suggests that very 
different proportions of PAHs are accumulat‑
ing in fetal tissues and it also underscores the 
fundamental principle that to really under‑
stand health risks we cannot afford to ignore 
the actual tissue levels in favor of exposure   
estimates alone.
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We appreciate the comments of Fowler et al. 
In their letter, they compared the maximal 
maternal inhalation level of poly  cyclic aro‑
matic hydro  carbons (PAHs) in Krakow, 
Poland (Choi et al. 2008), with the mean 
fetal liver dose in Aberdeen, United Kingdom 
(Fowler et al. 2008). The goal of this compari‑
son seems to have been to examine whether 
the fetal exposure concentration following 
trans  placental transfer of the PAHs is higher 
than the airborne concentration for the 
mother. This is an important question because 
in epidemiologic investigations of develop‑
mental and health consequences of pre  natal 
PAH exposure, researchers often assume 
comparability in maternal exposure level and 
fetal exposure dose. Fowler et al. propose two 
inferences in their comments: a) the fetal liver 
exposure concentration resulting from trans‑
placental transfer of the PAHs is higher than 
the maternal exposure concentration of air‑
borne PAHs; and b) the relative proportion 
of individual PAHs for the fetal liver might be 
different from those experienced by the moth‑
ers. However, the two studies differ in several 
important aspects. Direct fetal–maternal com‑
parison based on combining the data from 
the two studies as proposed by Fowler et al. is 
problematic for the following reasons. 
First, in our study (Choi et al. 2008) 
we targeted nonsmoking pregnant women 
with no known risks of adverse birth out‑
comes in Krakow, Poland. To preclude the 
possibility of confounding by heavy environ‑
mental tobacco smoke (ETS) exposure or 
unreported maternal cigarette smoking, we 
further restricted the mother–newborn pairs 
to those with umbilical cord cotinine con‑
centrations < 25 ng/mL in our analysis of the 
birth outcomes. Within our Polish cohort, 
mean (± SD) newborn and maternal plasma 
cotinine levels were 0.32 ± 0.88 and 0.28 ± 
0.24 ng/mL, respectively (Choi et al. 2006). 
Fetal cotinine levels reported by Fowler et al. 
(2008) for the smoking mothers (45.2 ± 2.5 
ng/mL, mean ± SE) were about 75‑fold higher 
than those for the nonsmoking mothers (0.6 
± 1.9 ng/mL). In contrast, the fetal liver con‑
centrations of benz[a]anthracene, benzo[ghi]
perylene, benzo[a]pyrene (BaP), chrysene, 
dibenzo[a,h]anthracene, and indeno[1,2,‑
‑cd]pyrene for the smoking mothers are 
lower than those of the non  smoking moth‑
ers by to 18–75% [Table 3 of Fowler et al. 
(2008)]. Lack of correlation between cotinine 
and PAH levels in the nonsmoking women 
raise doubt about the appropriateness of the 
compari  son based on their control group. 
Second, major sources of the PAHs in 
Krakow were coal‑ and diesel‑combustion 
(Choi et al. 2008). In contrast, the relative 
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Table 1. Maximum air PAH exposure (ng/m3) compared with mean human male fetal liver PAH levels (ng/kg 
dry weight) from mothers who did and did not smoke, during the second trimester. 
    PAH concentration      Relative proportion of PAH
  Maximum air  Liver mean  Maximum air  Liver mean
PAH  (ng/m3)  Nonsmoker  Smoker  (ng/m3)  Nonsmoker  Smoker 
BaA  39.69  331,000  195,000  11.14  95.47  93.80
Benzo[b]fluoranthene  67.47  1,300  1,800  18.93  0.38  0.87
Benzo[k]fluoranthene  20.33  500  1,000  5.71  0.14  0.48
Benzo[ghi]perylene  32.26  800  200  9.14  0.23  0.10
BaP  42.23  500  200  11.85  0.14  0.09
Chrysene  31.13  11,000  9,000  8.73  3.17  4.33
Dibenzo[a,h]anthracene  10.76  800  200  3.02  0.24  0.09
Indeno[1,2,3-cd]pyrene  50.20  800  500  14.09  0.23  0.24
Pyrene  61.96  0a  0  17.39  0  0
aBelow detection in human fetal livers.Environmental Health Perspectives  •  v o l u m e  117 | n u m b e r  4 | April 2009  A 141
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proportions of the fetal liver PAHs from 
the smoking and the non  smoking women 
reported by Fowler et al.(2008) are almost 
identical. This suggests that major sources 
of PAHs in this study are maternal smoking 
or intensive ETS exposure. In their letter, 
Fowler et al. observed that the relative pro‑
portion of the maternal airborne exposure 
(from our study) is very different from the 
similar proportions in the fetal liver. They 
interpret this as very different proportions 
of PAHs accumulating in the liver follow‑
ing the maternal inhalation. However, we 
suspect that the difference in relative propor‑
tions of maternal air and fetal liver PAHs is 
likely due to the differences in the sources of 
the PAHs between the two studies, as well as 
to differential accumulation. 
Third, it is unknown whether the demo‑
graphic and socioeconomic characteristics of 
the maternal cohorts of the two studies are 
similar enough to support the comparison of 
the maternal airborne concentration with the 
fetal liver level. The maternal cohort of Fowler 
et al. (2008) elected medical abortion; about 
half of these women smoked intensively dur‑
ing their pregnancy. In contrast, the women 
in our cohort (Choi et al. 2008) successfully 
carried their pregnancies and were more likely 
to engage in healthy behaviors. Therefore, 
residual confounding by the maternal behav‑
iors (such as micro  nutrient intake during 
pregnancy), socio  economic status, and genetic 
polymorphisms might have further contrib‑
uted to the differences in maternal air and 
fetal liver dose. 
A substantial body of evidence suggests 
that fetuses are much more susceptible to 
PAH‑induced carcinogenesis than are adults 
(Rice 1982; Soyka 1980), despite the likeli‑
hood that the transplacental dose of PAHs 
to the fetus is at least an order of magni‑
tude lower than the maternal tissue levels 
(Neubert and Tapken 1988; Withey et al. 
1993). Perera et al. (2004) reported that fetal 
PAH–DNA adduct levels were generally 
similar to those in the mothers; among ETS 
exposed mother–newborn pairs, the mean 
(± SD) maternal BaP–DNA adduct level was 
0.23 ± 0.16 per 108 nucleotides, and the fetal 
level was 0.24 ± 0.15 per 108 nucleotides. 
Among the non‑ETS exposed pairs, the mean 
maternal BaP–DNA adduct level was 0.21 ± 
0.12 per 108 nucleotides, and the fetal level 
was 0.24 ± 0.15 per 108 nucleotides (Perera 
et al. 2004). 
The issue raised by Fowler et al. in their 
letter is important because little is known about 
the actual concentration or type of PAHs that 
reach the fetus following maternal inhalation. 
Determining the actual fetal tissue dose is criti‑
cal in understanding the sources of fetal vul‑
nerability as well as the health effects of their 
exposure. However, the lack of comparability 
in maternal populations of the two studies does 
not allow valid estimation of the magnitude of 
maternal–fetal level difference. We believe the 
concentration of fetal tissue accumulation in 
humans following maternal inhalation of the 
PAHs needs further investigation. 
The authors declare they have no competing 
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Linear Low-Dose Extrapolation 
for Noncancer Responses Is 
Not Generally Appropriate
doi:10.1289/ehp.0800329
I disagree with the assertion of White et al. 
(2009) that linear low‑dose extrapolation is 
generally appropriate as a default for noncan‑
cer, as well as cancer, end points. Such a stance 
would radi  cally alter a basic tenet of toxicology 
and risk analysis, and any such course should 
be considered only after rigorous and broadly 
based examination of the scientific principles 
involved. 
White et al. (2009) offered only a cursory 
summary of arguments that were discussed 
in a 2007 workshop, but any fuller discus‑
sion that may have occurred in that work‑
shop was not recounted. Continual revisiting 
of the scientific thinking under  lying risk 
assessment policies is valuable, but a change 
of this nature—which would depart from 
decades of well‑established practice—needs 
to be carefully and critically examined. 
I believe that most observers would find 
fault with all of the proffered lines of reasoning 
that White et al. (2009) cited in advocating 
that noncancer dose–response relationships 
should be treated as linear. Although har‑
monization of cancer and non  cancer toxicity 
assessment holds some value (regarding com‑
monality of pharmaco  kinetics and, potentially, 
elements of modes of action), there are still 
fundamental differences between carcinogenic‑
ity on the one hand, in which the probability 
of constellations of rare events (that get rarer 
with lower doses) drives the dose–response 
function, and most non  cancer responses on 
the other, in which the dose–response func‑
tion hinges on the degree of perturbation of 
physiologic and homeo  static processes (which 
becomes less pronounced and less efficacious 
with lower doses) (Rhomberg 2004). 
The argument of White et al. (2009) that 
epidemiologic studies often show no thresh‑
olds, even for end points having thresholds 
in animal studies, is readily attributable to the 
small range of exposure levels and the approxi‑
mate nature of exposure measurements in 
most human studies; these artifically flatten 
apparent dose–response curves and tend to 
make any dose‑related effect (even those that 
are truly threshold in nature) look more or 
less linear as an artifact of the analysis. 
Heterogeneity in sensitivity and in modi‑
fying factors among people in the target 
population may tend to broaden the dose–
response relationship, but it does not linear‑
ize it, as White et al. (2009) asserted; indeed, 
the logic they invoked (the combined effect 
of variation in many modifying factors) leads 
to the expectation of a cumulative log‑normal 
dose–response function, which is always non‑
linear, rather than a linear one. 
Similarly, when examined rigorously, the 
invocation by White et al. (2009) of the prin‑
ciple of additivity to background fails to sup‑
port general linearity; unless it is framed in 
the discussion of a specific mode of action, the 
additivity‑to‑background argument amounts 
to begging the question—assuming the hypo‑
thetical existence of an underlying and rate‑
limiting no‑threshold mechanistic effect to 
argue for linearity of the end result caused 
by that process. In fact, many biological 
processes—notably homeostasis and switch A 142  v o l u m e  117 | n u m b e r  4 | April 2009  •  Environmental Health Perspectives
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mechanisms—are inherently non  linear, with 
threshold effects for their perturbation to a 
degree sufficient to have health consequences. 
A rigorous examination of how additivity to 
background affects dose response for different 
modes of action should be undertaken before 
its general applicability is assumed.
The approach taken when extrapolating 
dose–response relationships to low doses has 
profound impact on risk‑management deci‑
sion making. If a change is proposed that is 
to be justified by invoking general principles, 
then the bearing of those principles needs to 
be rigorously articulated, well understood, 
and evaluated through broad discussion and 
debate. At present, this discussion has yet to 
occur.
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Linear Low-Dose Extrapolation   
for Non-Cancer Responses: 
Burke et al. Respond
doi:10.1289/ehp.0800329R
In his letter, Rhomberg raises several issues 
concerning recom  mendations in our report 
of the workshop “Issues and Approaches 
to Low Dose–Response Extrapolation for 
Environmental Health Risk Assessment” 
(White et al. 2009). One recommendation of 
the workshop was to set aside the generally 
held presumption that dose–response func‑
tions should follow a threshold model when 
extrapolating from higher dose studies of non‑
carcinogenic responses to lower dose levels typ‑
ical for environmental exposures to chemicals. 
Workshop participants generally concluded 
that the selection of population‑level low‑dose 
extrapolation models should be informed by 
population factors such as inter  individual vari‑
ability in susceptibility and coexposures, as 
well as by categorization of mechanisms of 
toxicity. As indicated in the meeting report 
(White et al. 2009), most workshop partici‑
pants preferred a linear, no‑threshold approach 
to low‑dose extrapolation modeling, combined 
with modeled estimates of the low range of 
observed data, for non  cancer, as well as can‑
cer, outcomes in the absence of convincing 
evidence to indicate that an alternative model 
is more appropriate. We recognize that this 
recommendation represents a departure from 
current generally accepted practice.
On a nonsubstantive point, Rhomberg’s 
comment that we did not include additional 
information regarding “fuller discussions” 
at the workshop on this and other issues 
reflects the constraints imposed by EHP’s 
article length limits and changes made to 
accommodate reviewer comments encour‑
aging emphasis on workshop findings and 
recommendations rather than on workshop 
discussions.
We disagree with Rhomberg’s assertion 
that the finding of a linear, no‑threshold 
exposure–response relationship in many epi‑
demiologic studies of the effect of environ‑
mental pollutants, such as particulate matter 
and ozone air pollution, can be attributed 
entirely to a small range of exposures and 
measurement error. Although these factors 
need to be considered in evaluating epidemio‑
logic study results, modeling techniques such 
as non  parametric smoothing methods have 
demon  strated the capacity to identify potential 
threshold relationships even in the context of 
relatively extreme measurement error (Cakmak 
et al. 1999; Schwartz and Zanobetti 2000). 
As we noted in our meeting report 
(White et al. 2009), for the limited num‑
ber of chemicals and agents for which robust 
low‑dose response data exists (e.g., epide‑
miologic studies of large populations with 
exposures to particulate matter and ozone air 
pollution extending from relatively high to 
low ambient levels), thresholds have not been 
observed for non  cancer or cancer outcomes 
[U.S. Environmental Protection Agency 
(EPA) 2006a, 2006b]. Additionally, for some 
of the exposures considered, the mechanisms 
of action thought to underlie the observed 
effects have been characterized by some as 
threshold mechanisms (e.g., the disruption of 
the homeo  static conditions for reactive oxygen 
species). In such cases, interindividual variabil‑
ity, background disease processes, and coexpo‑
sures may explain the observed linearity.
Although we acknowledge that there are 
differences in the intrinsic biological processes 
involved in generating cancer and non  cancer 
outcomes, we disagree with Rhomberg’s asser‑
tion that hetero  geneity in intrinsic population 
susceptibility and additivity to background 
disease processes result in simply “broaden‑
ing” the dose–response relationship (which 
we presume means making the dose–response 
curve shallower). The underlying concept that 
additivity to background disease processes and 
variability in population susceptibility results 
in a linearization of the dose–response func‑
tion for populations exposed to environmen‑
tally relevant levels was originally discussed in 
the context of cancer outcomes [Crump et al. 
1976; Lutz 1990; National Research Council 
(NRC) 2005], and the suggestion that this 
same concept applies to non  cancer outcomes 
is not novel (Clewell and Crump 2005; 
Crawford and Wilson 1996). Similarly, the 
importance of considering inter  individual 
variability in assessing uncertainty associated 
with chemical risk assessments of non  cancer 
effects has been recognized (Hattis and Silver 
1994). The signifi  cance of these factors in 
the selection of dose–response models for 
use in environ  mental health risk assessment 
was also highlighted in a recent NRC report 
(NRC 2008).
Regarding the assumption of additivity 
to background disease on low‑dose extrapo‑
lation, in our meeting report (White et al. 
2009) we noted the importance of assessing, 
to the extent possible, whether the mode 
or mechanism of action of the key events 
involved are consistent. However, current 
knowledge of these detailed biologic pro‑
cesses is still quite limited for most chemicals 
and pollutants, and as noted by Hoel (1997) 
[L]ow‑dose linearity is speculative and it is a 
reasonable assumption for public health purposes 
in those instances where there is no scientific evi‑
dence to the contrary.
We recognize that uncertainty increases 
as the dose–response extrapolation extends 
farther below observed data. The findings 
regarding exposure–response relationships 
from large‑scale epidemiologic studies of 
environmental pollutants suggest that when 
considering population‑level dose–response 
factors, interindividual variability, additivity 
to background disease processes, coexpo‑
sures, and mechanisms of action, warrant 
careful consideration. As a consequence, we 
continue to recommend that the approach 
proposed in our meeting report (White et al. 
2009) is appropriate and necessary.
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Er r a t a
In Table 1 of the article by Tarantini et al. [Environ Health Perspect 117:217–222 (2009)], the 
sequence for the iNOS forward primer should be AATGAGAGTTGTTGGGAAGTGTTT 
instead of AATGAGAGTTGTTGTTGGGAAGTGTTT. 
The authors apologize for the error.
In the article “Diesel Exhaust Particles Activate the Matrix‑Metalloproteinase‑1 Gene in 
Human Bronchial Epithelia in a β‑Arrestin–Dependent Manner via Activation of RAS” by 
Li et al. [Environ Health Perspect 117:400–409 (2009)], the competing financial interest 
declaration was incorrect. Jinju Li was not supported by the Philip Morris grant but by a 
Leon‑Goldberg Fellowship.Therefore, the declaration should be as follows: 
S.A.S and W.L. received funding from Philip Morris USA and Philip Morris International. The other 
authors declare they have no competing financial interests.
In the February 2009 Focus article [“Carbon Offsets: Growing Pains in a Growing Market,” 
Environ Health Perspect 117:A62–A68 (2009)], a quotation at the bottom of p. A64 is 
incorrectly attributed to David Antinioli. The quotation should actually be attributed to Bill 
Burtis of Clean Air‑Cool Planet; Antinioli is affiliated with the Voluntary Carbon Standard 
Association. On p. A68 of the same article, a quotation by James Lovelock is incorrectly 
attributed to the 22 January 2009 issue of New Scientist; the quotation actually appeared in 
the 24 January 2009 issue. 
The December 2008 Focus article [“The Yuck Factor: When Disgust Meets Discovery,” 
Environ Health Perspect 116:A524–A527 (2008)] incorrectly stated on p. A525 that 
Fountain Valley, California, is north of Redwood City. Fountain Valley is actually south of 
Redwood City.
EHP regrets the errors. 